Raymond Miller

Pennsylvania

Ray Miller is a trusted intellectual property advisor to clients in a wide range of spaces. He adds value to each client’s IP estate by providing clear and pragmatic guidance that allows for efficient navigation of IP opportunities. Ray helps clients identify, protect, secure and optimize the value of their IP.

He advises on strategic patent prosecution, manufacturing and trade secret protection, and regulatory exclusivity strategies. Ray counsels materials science, pharmaceutical, medical device, biologics and digital therapeutics clients to allow them to obtain a sufficient return on their investment. Ray also manages freedom-to-operate, manufacturing and supply considerations on his clients’ behalf.

His clients include private equity and venture capital funds, pharmaceutical and biotechnology firms, world-class medical and research facilities, and Fortune 500 companies with well-developed intellectual property portfolios. Ray’s work often spans both patent and trade secret protection, particularly for clients with proprietary processes, data, or formulations.

Ray’s practice is transactional. His work includes helping companies evaluate and protect their confidential know-how and trade secrets during diligence and commercial transactions. He applies his deep understanding of the life and materials sciences in a diverse range of industries such as pharmaceuticals, biotechnology, energy, manufacturing, computer hardware, water and air purification, and specialty plastics and chemicals. Ray’s experience in pharmaceuticals and biotechnology extends to disciplines such as medicinal chemistry, genetics, nutraceuticals, proteomics, nanotechnology and tissue engineering.

Representative Experience

• Counseled clients in creating regulatory exclusivity strategies that allowed for approval of numerous products without composition of matter patents or, in some cases, without Orange Book-listed patents
• Represented a clinical-stage biopharmaceutical company in creating a pathway for patent and regulatory exclusivity for dermatological products
• Successfully represented clients in transition from private to public as well as transition from clinical stage to marketing stage for pharmaceutical and biological products
• Established a comprehensive trade secret program at a publicly listed battery company which became key evidence in helping dismiss a misappropriation claim by a key competitor.
• Represented a company in creating patent and regulatory exclusivity for a topical cream
• Successfully extended the exclusivity rights of a publicly traded biotechnology company’s patent portfolio beyond its natural life, with its patent portfolio extension valued in excess of US$500 million
• Counseled a global healthcare company in its more than US$1 billion equity investment.
• Successfully navigated the ITC on behalf of a chemical manufacturing company in defense of patent infringement allegations